ACADIA PHARMACEUTICALS INC - 8-K Filing

Acadia Pharmaceuticals reports Q3 2026 GAAP total revenues of $342 million, up 23% YoY, and raises full-year DAYBUE net sales guidance. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ACAD

Read the full article at SEC EDGAR

More Regulatory news